TY - JOUR
T1 - What electrophysiology tells us about Alzheimer's disease
T2 - a window into the synchronization and connectivity of brain neurons
AU - Babiloni, Claudio
AU - Blinowska, Katarzyna
AU - Bonanni, Laura
AU - Cichocki, Andrej
AU - De Haan, Willem
AU - Del Percio, Claudio
AU - Dubois, Bruno
AU - Escudero, Javier
AU - Fernández, Alberto
AU - Frisoni, Giovanni
AU - Guntekin, Bahar
AU - Hajos, Mihaly
AU - Hampel, Harald
AU - Ifeachor, Emmanuel
AU - Kilborn, Kerry
AU - Kumar, Sanjeev
AU - Johnsen, Kristinn
AU - Johannsson, Magnus
AU - Jeong, Jaeseung
AU - LeBeau, Fiona
AU - Lizio, Roberta
AU - Lopes da Silva, Fernando
AU - Maestú, Fernando
AU - McGeown, William J.
AU - McKeith, Ian
AU - Moretti, Davide Vito
AU - Nobili, Flavio
AU - Olichney, John
AU - Onofrj, Marco
AU - Palop, Jorge J.
AU - Rowan, Michael
AU - Stocchi, Fabrizio
AU - Struzik, Zbigniew M.
AU - Tanila, Heikki
AU - Teipel, Stefan
AU - Taylor, John Paul
AU - Weiergräber, Marco
AU - Yener, Gorsev
AU - Young-Pearse, Tracy
AU - Drinkenburg, Wilhelmus H.
AU - Randall, Fiona
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Electrophysiology provides a real-time readout of neural functions and network capability in different brain states, on temporal (fractions of milliseconds) and spatial (micro, meso, and macro) scales unmet by other methodologies. However, current international guidelines do not endorse the use of electroencephalographic (EEG)/magnetoencephalographic (MEG) biomarkers in clinical trials performed in patients with Alzheimer's disease (AD), despite a surge in recent validated evidence. This position paper of the ISTAART Electrophysiology Professional Interest Area endorses consolidated and translational electrophysiological techniques applied to both experimental animal models of AD and patients, to probe the effects of AD neuropathology (i.e., brain amyloidosis, tauopathy, and neurodegeneration) on neurophysiological mechanisms underpinning neural excitation/inhibition and neurotransmission as well as brain network dynamics, synchronization, and functional connectivity, reflecting thalamocortical and corticocortical residual capacity. Converging evidence shows relationships between abnormalities in EEG/MEG markers and cognitive deficits in groups of AD patients at different disease stages. The supporting evidence for the application of electrophysiology in AD clinical research as well as drug discovery pathways warrants an international initiative to include the use of EEG/MEG biomarkers in the main multicentric projects planned in AD patients, to produce conclusive findings challenging the present regulatory requirements and guidelines for AD studies.
AB - Electrophysiology provides a real-time readout of neural functions and network capability in different brain states, on temporal (fractions of milliseconds) and spatial (micro, meso, and macro) scales unmet by other methodologies. However, current international guidelines do not endorse the use of electroencephalographic (EEG)/magnetoencephalographic (MEG) biomarkers in clinical trials performed in patients with Alzheimer's disease (AD), despite a surge in recent validated evidence. This position paper of the ISTAART Electrophysiology Professional Interest Area endorses consolidated and translational electrophysiological techniques applied to both experimental animal models of AD and patients, to probe the effects of AD neuropathology (i.e., brain amyloidosis, tauopathy, and neurodegeneration) on neurophysiological mechanisms underpinning neural excitation/inhibition and neurotransmission as well as brain network dynamics, synchronization, and functional connectivity, reflecting thalamocortical and corticocortical residual capacity. Converging evidence shows relationships between abnormalities in EEG/MEG markers and cognitive deficits in groups of AD patients at different disease stages. The supporting evidence for the application of electrophysiology in AD clinical research as well as drug discovery pathways warrants an international initiative to include the use of EEG/MEG biomarkers in the main multicentric projects planned in AD patients, to produce conclusive findings challenging the present regulatory requirements and guidelines for AD studies.
KW - Alzheimer's disease (AD)
KW - Electroencephalography and magnetoencephalography (EEG and MEG)
KW - Event-related potentials and magnetic fields
KW - Preclinical and clinical research
KW - Resting-state condition
KW - The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART)
UR - http://www.scopus.com/inward/record.url?scp=85074925638&partnerID=8YFLogxK
U2 - 10.1016/j.neurobiolaging.2019.09.008
DO - 10.1016/j.neurobiolaging.2019.09.008
M3 - Review article
C2 - 31739167
AN - SCOPUS:85074925638
VL - 85
SP - 58
EP - 73
JO - Neurobiology of Aging
JF - Neurobiology of Aging
SN - 0197-4580
ER -